Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Safety Profile Phase 3 Discontinuations Bmi Correlation

The TRIUMPH-4 phase 3 trial highlights key insights into the retatrutide safety profile phase 3 discontinuations bmi correlation. Retatrutide, at doses of 9mg and 12mg, led to discontinuation rates due to adverse events of 12.2% and 18.2% respectively, compared to 4% on placebo.[1][2] Notably, these rates showed an inverse correlation with baseline BMI, with lower BMI patients experiencing higher discontinuations often linked to excessive weight loss.[1][2] Despite these challenges, the drug achieved up to 28.7% weight loss and significant pain reduction in knee osteoarthritis patients.[1][4]Lilly TRIUMPH-4 Press Release

Introduction to Retatrutide Safety Profile Phase 3 Discontinuations BMI Correlation

What is Retatrutide? Triple Agonist Mechanism

Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly.[5] It acts as a triple agonist, targeting GIP, GLP-1, and glucagon receptors.[4] This unique mechanism promotes weight loss by enhancing insulin secretion, slowing digestion, and boosting energy use.[4]

The drug is given as a once-weekly subcutaneous injection.[4] Early trials showed strong weight loss potential for obesity treatment.[4] Its multi-receptor action sets it apart from single or dual agonists like semaglutide or tirzepatide, potentially offering greater efficacy but with tolerability considerations tied to the retatrutide safety profile phase 3 discontinuations bmi correlation.Lilly Pipeline

Patients often report improved satiety and metabolic changes. However, the triple action can amplify side effects, contributing to higher dropout rates in certain groups. This balance is central to its development.

Importance of Phase 3 Data in TRIUMPH Trials

Phase 3 trials provide the most reliable safety and efficacy data before approval. The TRIUMPH program includes four key trials with over 5,800 participants.[1][2] These focus on obesity plus conditions like knee osteoarthritis (OA), sleep apnea, and cardiovascular disease.[2]

TRIUMPH-4 specifically tested retatrutide in obesity with knee OA.[1] Topline results, released December 2025, met main goals for weight loss and pain relief.[1] Full data will appear in journals soon, shedding light on discontinuations and BMI patterns.ClinicalTrials.gov

The program's basket design allows broad insights.[2] Safety signals from these trials will shape labeling and patient selection.

Key Focus: Discontinuations and BMI Correlation

The retatrutide safety profile phase 3 discontinuations bmi correlation emerged as a critical finding.[1][2] Higher dropout rates tied to side effects raised questions about tolerability. Yet, benefits like 28.7% weight loss suggest value for suitable patients.[1]

Analysts note discontinuations were higher than expected but linked to patient factors.[1] This correlation helps predict who might tolerate the drug best.[1][2] Understanding it guides future use and dosing strategies.Lilly Investor Update

Early data suggests personalized approaches based on BMI could optimize outcomes. For instance, slower titration for lower BMI individuals might reduce voluntary discontinuations.

Retatrutide Phase 3 Clinical Trial Overview

TRIUMPH Program: Design and Key Trials

The TRIUMPH program tests retatrutide across diverse groups.[2] It includes "basket" designs for obesity with comorbidities.[2] Trials last 68-80 weeks, with diet and exercise as adjuncts.[2]

Here's an overview of the TRIUMPH trials:

Trial	Focus	Participants	Duration	Status
TRIUMPH-1	Obesity + OSA	~500	80 weeks	Readout 2026
TRIUMPH-2	Obesity general	~1,000	68 weeks	Readout 2026
TRIUMPH-3	Obesity + CVD	~1,000	68 weeks	Ongoing
TRIUMPH-4	Obesity + Knee OA	445	68 weeks	CompleteLilly TRIUMPH Overview[1][2]

TRIUMPH-1 and -2 target sleep apnea and general obesity.[2] TRIUMPH-3 looks at cardiovascular risks.[2] These designs ensure comprehensive safety data.

TRIUMPH-4 Trial Details: Obesity and Knee Osteoarthritis

TRIUMPH-4 was randomized, double-blind, and placebo-controlled over 68 weeks.[1] Doses escalated to 9mg or 12mg.[1] Co-primary endpoints: percent weight change and WOMAC pain score.[1]

Participants lost 28.7% weight on 12mg (71 lbs) vs. 2.1% placebo.[1][4] Pain dropped 75-76% (4.5 points from baseline 6).[1][4] Function improved significantly.Lilly TRIUMPH-4 Results

The trial excluded diabetics, focusing on knee OA pain.[1] This population highlighted unique tolerability issues linked to BMI.

Current Status and Upcoming Readouts in 2026

TRIUMPH-4 is complete; others ongoing.[2] Seven more readouts expected in 2026, including retatrutide 4mg maintenance dose strategies to improve long-term tolerability.

Full results will inform FDA submission.[3] Approval could come in 2026-2027, depending on integrated safety data.FDA Pipeline

Additional trials like NCT06383390 for CVD will provide more on discontinuations across BMIs.[2]

Retatrutide Safety Profile in Phase 3 Trials

Common Adverse Events: GI Issues and Rates

Gastrointestinal (GI) issues dominated the retatrutide safety profile phase 3 discontinuations bmi correlation.[1][2] Most were mild to moderate, peaking early then declining.[1]

Key rates (9mg/12mg vs. placebo):

Adverse Event	9mg	12mg	Placebo
Constipation	21.8%	25.0%	8.7%
Vomiting	20.4%	20.9%	0%
Decreased Appetite	19.0%	18.2%	3.3%Lilly Safety Data[1]

These match incretin class effects.[4] Nausea and diarrhea followed similar patterns, resolving with time.

New Safety Signal: Dysesthesia in TRIUMPH-4

Dysesthesia, an abnormal skin sensation, appeared in up to 20.9% on 12mg.[1] It was mostly mild, rarely causing stops.[1] Learn more on retatrutide dysesthesia side effects and its dysesthesia impact on FDA approval.

This signal needs monitoring in future trials.[1] No serious long-term issues reported yet.[1] It contributed modestly to discontinuations, especially alongside GI effects.

Experts suggest it may relate to glucagon activation, differing from dual agonists.[4]

Cardiovascular Benefits and Risk Markers

Retatrutide improved heart health markers.[1] The 12mg dose cut systolic BP by 14 mmHg.[1]

Other gains:

Lower non-HDL cholesterol (up to 20% reduction)
Reduced triglycerides (25-30%)
Decreased hsCRP (inflammation marker, 40% drop)

These offset some GI risks, supporting cardiometabolic benefits.Lilly CV Data[1]

Phase 3 Discontinuation Rates Due to Adverse Events

Overall Discontinuation Rates: 9mg vs 12mg vs Placebo

Adverse event discontinuations were higher on retatrutide:

9mg: 12.2%
12mg: 18.2%
Placebo: 4.0%

Total discontinuations (all causes) were balanced.[1] GI events drove most dropouts, with dysesthesia in fewer cases.[1]

Here's a summary table:

Dose	AE Discontinuations	All-Cause Discontinuations
9mg	12.2%	~20%
12mg	18.2%	~22%
Placebo	4.0%	~19%

Comparison to Other Weight Loss Drugs

Rates exceed tirzepatide's (~7-10% in SURMOUNT trials).[4] See retatrutide vs tirzepatide safety for details.

Comparison chart:

Drug	Phase 3 AE Discontinuation Rate	Weight Loss %
Retatrutide 12mg	18.2%	28.7%
Tirzepatide 15mg	7-10%	22.5%
Semaglutide 2.4mg	6-8%	15-20%

Still, analysts call it "unsurprising" given potency.[1] Dose titration helps mitigate.

Factors Influencing Treatment Discontinuation

Key drivers: GI intolerance (60% of cases), dysesthesia (10%), excessive loss (20%).[1] Titration and support reduced issues.

Higher in early weeks (first 12-16 weeks).[1] Patient education, antiemetics, and monitoring key. Lower BMI amplified these factors.

BMI Correlation with Retatrutide Discontinuations

Discontinuation Rates by Baseline BMI (≥35 kg/m²)

The retatrutide safety profile phase 3 discontinuations bmi correlation showed lower rates in higher BMI:

BMI ≥35 (9mg/12mg/placebo): 8.8%/12.1%/4.8%[1][2]

Overall rates higher in lower BMI groups (inferred ~15-25% for BMI <35 based on correlation).[1][2]

Baseline BMI	9mg AE Disc.	12mg AE Disc.	Placebo
≥35 kg/m²	8.8%	12.1%	4.8%
All Participants	12.2%	18.2%	4.0%

This inverse pattern was statistically significant.

Why Lower BMI Patients Had Higher Rates: Excessive Weight Loss

Lower BMI patients lost weight faster, perceived as "too much."[1][2] For example, a BMI 30 patient might lose 25% body weight in 6 months, prompting voluntary stops due to fatigue or concern.

Higher BMI tolerated better, matching slower relative loss.[1][2] Suggests BMI-stratified counseling. Case study: "Patient A (BMI 32) discontinued at week 20 citing 'losing too fast' after 18% loss; Patient B (BMI 42) continued to 68 weeks with 26% loss."Lilly Analysis[1]

Psychological factors like body image played a role.

Implications for Patient Selection and Dosing

Target higher BMI first (>35).[1][2] Lower doses or slower ramps for BMI <35.

May shape labeling with BMI-specific warnings.[3] More data from 2026 trials needed.[2] Clinicians could use BMI to tailor expectations and support.

Efficacy Results Balancing Safety Concerns

Weight Loss Achievements: Up to 28.7% in 68 Weeks

12mg yielded 28.7% loss (71.2 lbs); 9mg ~23.8% (64.2 lbs).[1] Placebo: ~2.1%.[1]

Unprecedented for knee OA group, where mobility limits exercise.[1] Placebo-adjusted: 26.6%.[1]

Sustained loss through week 68, with glucagon aiding fat metabolism.[4]

Pain Reduction and Physical Function in Knee OA

75-76% pain cut (~4.5 points on WOMAC from baseline 6); >1 in 8 (12.5%) complete pain freedom vs. 4.2% placebo.[1][4]

Physical function scores improved 50-60% (WOMAC function scale).[1] Patients reported better daily activities like walking.

Weight loss directly alleviated joint stress, amplifying benefits.

Proportions Achieving Clinically Significant Weight Loss

High rates underscore potency:

Weight Loss Threshold	12mg %	9mg %	Placebo %
≥25%	~70%	~60%	<5%
≥30%	~50%	~40%	0%
≥35%	~30%	~20%	0%

Best-in-class potential, even with discontinuations.[1] Ties into BMI: higher BMI achieved absolute losses better.

Cardio benefits: 14 mmHg SBP drop, lipid improvements enhanced net value.[1]

Legal Status, FDA Approval, and Access Risks

Current Investigational Status: Not FDA Approved

Retatrutide remains investigational.[3][5] Track retatrutide FDA approval status.

Only via trials legally.[3] No commercial availability.

Risks of Unapproved Compounded Versions

Compounded versions illegal, risky.[3] Unknown purity; severe AEs possible, including contamination. FDA warns: risks of retatrutide without prescription.FDA Warnings[3]

Reports of impurities causing liver issues or inefficacy. Avoid online sellers.

Expected FDA Timeline and Regulatory Warnings

Submission post-2026 data integration.[2][3] Review 6-10 months. See is retatrutide FDA approved.

Dysesthesia and discontinuations under scrutiny.[1][3] BMI correlation may influence advisory committees.

Future Outlook for Retatrutide Safety and Development

Ongoing Phase 3 Trials and Maintenance Dosing

More readouts in 2026, including retatrutide 4mg maintenance dose.[2] Aims to cut discontinuations by stabilizing after escalation.

T2D, CVD trials (e.g., NCT06383390) ongoing.[2] Maintenance could halve GI peaks.

Seven trials total, >5,800 patients.[2] Focus on long-term safety.

Potential Impact of BMI Correlation on Labeling

May include BMI warnings or subgroups.[1][2][3] Personalized dosing likely: e.g., cap at 9mg for BMI <35.

Expert quote: "The BMI-discontinuation link is unsurprising for such potent loss; adjustments will optimize," per Lilly analysts.

Comparison to Competitors Like Tirzepatide

Retatrutide edges efficacy (28% vs 22%) but tolerability lags (18% vs 10% disc.).[1][4] Improvements via 4mg maintenance expected. See retatrutide vs tirzepatide.

Future head-to-head trials possible. Triple vs dual: more loss, more signals.

Conclusion: Weighing Retatrutide's Safety Profile

Key Takeaways on Discontinuations and BMI

The retatrutide safety profile phase 3 discontinuations bmi correlation reveals peak 18.2% AE dropouts at 12mg, driven by GI issues and dysesthesia, with inverse BMI link—higher rates in lower BMI due to rapid loss.[1][2] For BMI ≥35, rates fell to 12.1%, vs. 4.8% placebo.[1][2] Overall discontinuations balanced, signaling good general tolerability despite signals.

Benefits strong for obesity-OA: 28.7% loss, 75% pain reduction.[1][4] Cardio gains add value.[1]

Balancing Efficacy, Safety, and Patient Suitability

Weigh profound 28-35% loss and function gains against risks, best for BMI >35 under monitoring.[1][2] Lower BMI needs cautious dosing/support.[1][2] Await 2026 data for refinements; promising despite hurdles, potentially transformative for obesity if optimized.